PTH and Hypercalcemia: Differences in effectiveness with regard to PTH reduction and 25(OH)D levels, and in hypercalcaemia in these analyses are likely explained by the lack of pharmacological surges with ERC that are associated with nutritional vitamin D and active vitamin D/its analogues, and the potential benefits of avoiding negative feedback from a ‘spike’ in 25(OH)D [52].